Show simple item record

dc.contributor.authorSchild, LJen_US
dc.contributor.authorPhillips, DHen_US
dc.contributor.authorOsborne, MRen_US
dc.contributor.authorHewer, Aen_US
dc.contributor.authorBeland, FAen_US
dc.contributor.authorChurchwell, MIen_US
dc.contributor.authorBrown, Ken_US
dc.contributor.authorGaskell, Men_US
dc.contributor.authorWright, Een_US
dc.contributor.authorPoirier, MCen_US
dc.identifier.citationMUTAGENESIS, 2005, 20 pp. 115 - 124en_US
dc.description.abstractLiver homogenates from rats fed tamoxifen (TAM) in the diet were shared among four different laboratories. TAM-DNA adducts were assayed by high pressure liquid chromatography-electrospray tandem mass spectrometry (HPLC-ES-MS/MS), TAM-DNA chemiluminescence immunoassay (TAM-DNA CIA), and P-32-postlabeling with either thin layer (P-32-P-TLC) or liquid chromatography (P-32-P-HPLC) separation. In the first study, rats were fed a diet containing 500 p.p.m. TAM for 2 months, and the values for measurements of the (E)-alpha-(deoxyguanosin-N-2-yl)-tamoxifen (dG-N-2-TAM) adduct in replicate rat livers varied by 3.5-fold when quantified using ‘in house’ TAM-DNA standards, or other approaches where appropriate. In the second study, rats were fed 0, 50, 250 or 500 p.p.m. TAM for 2 months, and TAM-DNA values were quantified using both ‘in house’ approaches as well as a newly synthesized [N-methyl-H-3]TAM-DNA standard that was shared among all the participating groups. In the second study, the total TAM-DNA adduct values varied by 2-fold, while values for the dG-N-2-TAM varied by 2.5-fold. Ratios of dG-N-2-TAM:(E)-alpha-(deoxyguanosin-N-2-yl)-N-desmethyltamoxifen (dG-N-2-N-desmethyl-TAM) in the second study were similar to 1:1 over the range of doses examined. The study demonstrated a remarkably good agreement for TAM-DNA adduct measurements among the diverse methods employed.en_US
dc.format.extent115 - 124en_US
dc.publisherOXFORD UNIV PRESSen_US
dc.titleHepatic DNA adduct dosimetry in rats fed tamoxifen: a comparison of methodsen_US
dc.typeJournal Article
rioxxterms.typeJournal Article/Reviewen_US
pubs.notesaffiliation: Poirier, MC (Reprint Author), NCI, Carcinogen DNA Interact Sect, NIH, Bldg 37,Room 4032m37 Convent Dr MSC-4255, Bethesda, MD 20892 USA. NCI, Carcinogen DNA Interact Sect, NIH, Bethesda, MD 20892 USA. Inst Canc Res, Sutton SM2 5NG, Surrey, England. Natl Ctr Toxicol Res, Div Biochem Toxicol, Jefferson, AR 72079 USA. Univ Leicester, Bioctr, Canc Biomarkers & Prevent Grp, Leicester LE1 7RH, Leics, England. keywords-plus: TANDEM MASS-SPECTROMETRY; BREAST-CANCER; ALPHA-HYDROXYTAMOXIFEN; HUMAN ENDOMETRIUM; IN-VITRO; N-DESMETHYLTAMOXIFEN; METABOLIC-ACTIVATION; LIVER CELLS; IDENTIFICATION; TRIALS research-areas: Genetics & Heredity; Toxicology web-of-science-categories: Genetics & Heredity; Toxicology author-email: orcid-numbers: Phillips, David/0000-0001-8509-3485 Beland, Frederick/0000-0002-2113-6260 number-of-cited-references: 44 times-cited: 14 usage-count-last-180-days: 0 usage-count-since-2013: 1 journal-iso: Mutagenesis doc-delivery-number: 919SB unique-id: ISI:000228636800006 oa: gold_or_bronze da: 2018-09-10en_US
pubs.notesNot knownen_US
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Closed research teams
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Closed research teams/Human Biomonitoring & Carcinogen Activation
pubs.embargo.termsNot knownen_US
icr.researchteamHuman Biomonitoring & Carcinogen Activationen_US
dc.contributor.icrauthorPhillips, David Hunteren_US
dc.contributor.icrauthorHewer, Alanen_US

Files in this item


There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record